MELPHALAN RESISTANCE IN MYELOMA

被引：8

作者：

HALL, A ^{[1
]}

PROCTOR, SJ ^{[1
]}

HARRIS, AL ^{[1
]}

机构：

[1] ROYAL VICTORIA INFIRM, DEPT ONCOL, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 1986年 / 63卷 / 01期

关键词：

D O I：

10.1111/j.1365-2141.1986.tb07488.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1 / 6

页数：6

共 33 条

[1] EFFECTIVE TREATMENT OF ADVANCED MULTIPLE-MYELOMA REFRACTORY TO ALKYLATING-AGENTS [J].

BARLOGIE, B ;

SMITH, L ;

ALEXANIAN, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (21) :1353-1356

[2]

BEGLEITER A, 1979, CANCER RES, V39, P353

[3]

BHALLA K, 1985, CANCER RES, V45, P3657

[4]

BIEDLER JL, 1983, CANCER TREAT REP, V67, P859

[5] PHARMACOKINETICS OF ORAL AND INTRAVENOUS MELPHALAN DURING ROUTINE TREATMENT OF MULTIPLE-MYELOMA [J].

BOSANQUET, AG ;

GILBY, ED .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1982, 18 (04) :355-362

[6] TUMOUR SULPHYDRYL LEVELS AND SENSITIVITY TO NITROGEN MUSTARD MEROPHAN [J].

CALCUTT, G ;

CONNORS, TA .

BIOCHEMICAL PHARMACOLOGY, 1963, 12 (08) :839-&

[7] IMPROVED SURVIVAL TIMES IN MULTIPLE-MYELOMA TREATED WITH MELPHALAN, PREDNISONE, CYCLOPHOSPHAMIDE, VINCRISTINE AND BCNU - M-2 PROTOCOL [J].

CASE, DC ;

LEE, BJ ;

CLARKSON, BD .

AMERICAN JOURNAL OF MEDICINE, 1977, 63 (06) :897-903

[8]

DANTZIG AH, 1981, FED PROC, V40, P1894

[9]

DUFOUR M, 1985, CANCER CHEMOTH PHARM, V15, P125

[10]

DURIE BGM, 1982, CLIN HAEMATOL, V11, P181

← 1 2 3 4 →